Page 2
-
Insulet’s Eric Benjamin shares update on automated insulin delivery system
The chief product and customer experience officer said Insulet has seen an uptick in users with Type 2 diabetes since receiving an expanded indication, and shared an update on plans for a closed-loop system.
-
MedTech Europe urges EU to exclude devices, diagnostics from trade war
MedTech Europe said the EU’s list of products it could target in retaliation for U.S. actions “includes over 800 trade codes related to medical technologies.”
-
Virtual Incision appoints former Intuitive exec as CEO
Virtual Incision has selected Jim Alecxih as its new CEO as the company prepares a series of FDA submissions for its next robotic surgery system, called M2.
-
5 things to watch at the ADA’s Scientific Sessions
The American Diabetes Association’s annual conference kicks off amid a dynamic year for diabetes tech, as access improves for people with Type 2 diabetes and companies debut new devices.
-
Rise in VC activity tees up ‘strong year’ for medtech funding: PitchBook
Improvements in VC funding contrasted with M&A activity, which has fallen short of the level PitchBook predicted under the Trump administration.
-
Dexcom recalls more than 700,000 CGM receivers for lack of audible alarm
Severe adverse events, including seizure and loss of consciousness, were potentially linked to the issue, based on 56 reports Dexcom received.
Updated 14 hours ago -
Medtronic training pact includes Hugo robot, cardiac ablation tech
The medical device maker is partnering with IRCAD, a surgical education and research institute, to train medical personnel in cardiovascular, neuroscience and minimally invasive specialties.
-
Q’Apel recalls clot removal device in response to FDA warning letter
Rather than pursuing a new regulatory pathway, Q'Apel said it is discontinuing the recalled system “as part of its strategic shift toward newer technologies.”
-
Could the FDA take an indirect approach to regulate LDTs?
Attorneys said many questions remain about LDT regulation after the FDA lost its legal fight. A recent warning letter could be a clue to future enforcement.
-
Anne Wojcicki wins bid to buy back 23andMe for $305M
A nonprofit led by the co-founder and former CEO of 23andMe outbid competitors for nearly all of the company’s assets.